Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org

April 2009

 



Events Column
Save the date! CURE/Yale BioHaven 2008-09 Seminar Series more
4/15  5:15 pm - 7:30 pm. MIT Enterprise Forum of CT. "Accelerating Renewable Energy Technology Commercialization." Omni Hotel at Yale, 155 Temple Street, New Haven. more
5/1  9:00 am - 8:30 pm. Pitch presentations begin at Yale Entrepreneurial Society Y50K Competition. more
5/6  3:30 pm - 6:30 pm. CURE/Yale BioHaven: Affomix. Anlyan Center, 300 Cedar Street, New Haven. more

Connecticut Emerging As Stem Cell Power
From the desk of Paul Pescatello, President and CEO of CURE
UConn's investment of time and energy in its women's basketball program paid off once again April 7 when the Huskies beat the Louisville Cardinals 76-54. Another Connecticut program that's paying off is the State's investment in stem cell research. While stem cell therapies for such debilitating illnesses as diabetes, Parkinson's disease, and multiple sclerosis are still some years away, it is clear that progress is being made.
For the full story
Stem Cell Research Vital Driver of CT Bioscience
On March 31 the State of Connecticut Stem Cell Research Advisory Committee directed an additional $9.8 million in stem cell research funds, the third installment of grants from a Stem Cell Research Fund pledged to provide $100 million in funding over 10 years. The awards came just one week after StemCONN 09, an international symposium, brought scientists from around Connecticut, the United States, and the world to New Haven to discuss the latest stem cell research findings.
For the full story
CellDesign Presents at CURE/Yale BioHaven
CellDesign, Connecticut's first and only commercial enterprise entirely devoted to stem cell technology, gave a presentation March 25 at the Anlyan Center in New Haven as part of the CURE/Yale BioHaven series. Speaking were John Hambor, Ph.D., chief executive officer of the company, and Linda Powers, J.D., co-founder and managing director of Toucan Capital, Inc., a venture capital firm that is the leading U.S. investor in stem cells and regenerative medicine and the major investor in CellDesign.
For the full story
CURE Member News Digest
 454 Life Sciences reports study of diabetes-lowering gene
 Achillion expects advances in clinical program
 Alexion tells of Australian approval
 Bristol-Myers Squibb reports Plavix® results
 CellDesign signs agreement with Stemgent
 Connecticut Innovations ups investment in Helix
 CuraGen names Forsgren to new board position
 Danbury Hospital reports double mammary coronary bypass
 Genomas inducted into AIMBE
 GlaxoSmithKline in agreement on Vyvanse®
 Hartford Hospital names Handle VP of Cancer Program
 Helix Therapeutics gets $515,000 more from CI
 Ipsogen pleased with 2008 performance
 Johnson & Johnson marks Cordis 50th anniversary
 MannKind submits NDA to FDA
 Marinus meets Phase 2 endpoint for epilepsy drug
 NanonViricides in pact with 'major pharma'
 Neurogen comments on 2008 results
 Pfizer reports CHANTIX/CHAMPIX® study
 PhRMA issues health reform statement
 Svigals+Partners promotes two to associate principal
 UConn studies cost of 'defensive medicine'
 Yale sheds new light on Alzheimer's pathway
For the full story
 
 
Copyright 2009 © Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
Click here for Archive of back issues.
Newsletter developed and edited by HarveyMalis Communications LLC, Guilford, Conn.

Managing Your Subscriptions
Click on the "Manage your subscription" link below and then on "Edit Your Profile." To subscribe to a publication, type a "y" in the box to the right of the publication name. To unsubscribe, leave the box blank.